Prescient Therapeutics: Investor Briefing with CEO James McDonnell
CEO and Managing Director, James McDonnell, held an investor briefing with Reach Markets, where he discussed the next critical phase towards approval and commercialisation of PTX-100.
In this session, James discusses how:
- How PTX-100’s Phase 1b results – which significantly exceeded benchmark expectations and existing drugs – provide a strong basis as we move into Phase 2 clinical trials.
- How the FDA’s Orphan Drug Designation and its acceptance of the Phase 2 clinical trial could lead to a fast-track designation for PTX-100 and closer to commercialisation – with a A$1bn+ market in the US alone.
- Why PTX-100 is just one application of Prescient’s much broader RAS Family inhibitor technology, which has potential applications for 22% of cancer cases world-wide.
Recorded on 31 March 2025 at 12pm (AEDT)
Featured Speaker
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
